Abstract: The invention is a lighting device that establishes an optimum circadian rhythm profile for a user by monitoring the sleep-wake cycles of the user over a period and controlling a light source based on the profile. The lighting device includes a feedback control system that receives sensory and user inputs to inform the system regarding the operation of the system and the light output. The light output of the lighting device is adjusted to improve the circadian rhythm of the user.

Abstract: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.

Abstract: This invention features a template for synthesizing combinatorial libraries, methods of synthesizing combiatorial libraries of chemical compounds utilizing the template, and combinatorial libraries of chemical compounds formed by the methods of this invention.

Abstract: The present invention relates to water soluble, camptothecin derivatives of formula (I), ##STR1## wherein: 1) R.sup.1 and R.sup.2 represent independently, hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy lower alkyl;ii) R.sup.1 represents hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl or lower alkoxy lower alkyl, and R.sup.2 represents --COR.sup.3,wherein:R.sup.3 represents hydrogen, lower alkyl, perhalo-lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy or lower alkoxy lower alkyl; oriii) R.sup.1 and R.sup.2 taken together with the linking nitrogen form a saturated 3 to 7 atom heterocyclic group of formula (IA) ##STR2## wherein: Y represents O, S, SO, SO.sub.2, CH.sub.2 or NR.sup.4wherein:R.sup.

Abstract: Compounds are described of the formula ##STR1## wherein: R.sup.1 is C.sub.3-6 alkyl or C.sub.1-3 alkylthioC.sub.1-3 alkyl;R.sup.2 is an optionally substituted C.sub.1-6 alkyl or C.sub.1-6 alkoxy group, aryl, heteroaryl, arylC.sub.1-4 alkyl, heteroarylC.sub.1-4 alkyl or a side-chain of a natural .alpha.-amino acid;R.sup.3 is hydrogen, C.sub.1-6 alkyl, CHR.sup.4 COR.sup.5 (where R.sup.4 is a side-chain of a natural .alpha.-amino acid and R.sup.5 is hydroxyl, C.sub.1-6 alkoxy or NHR.sup.6 where R.sup.6 represents a hydrogen atom or a C.sub.1-6 alkyl group) or a group (CH.sub.2).sub.n X (where n is 1 to 6 and X is hydroxyl, C.sub.1-4 alkoxy, heteroaryl or a group NR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are each hydrogen or C.sub.1-6 alkyl or the group NR.sup.7 R.sup.

Abstract: 2-[2-(1,4-Benzodioxanyl)]-2-imidazoline or a non-toxic salt thereof, substantially free of 2-[2-(2-methyl-1,3-benzodioxyl)]- 2-imidazoline or a non-toxic salt thereof.2-[2-(1,4-Benzodioxanyl)]-2-imidazoline or a non-toxic salt thereof characterised in that the nuclear magnetic resonance spectrum of the compound in a protonated form exhibits multiplets in the region of .tau.4.4 and .tau.5.4.Process for the preparation of 2-[2-(1,4-benzodioxanyl)]-2-imidazoline, pharmaceutical compositions thereof or of its salts, and their use as presynaptic .alpha..sub.2 -adrenoreceptor antagonists.

Abstract: This disclosure relates to a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 are independently selected from the class consisting of hydrogen, halo, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkoxy;R.sup.3 and R.sup.4 are independently hydrogen or C.sub.1 -C.sub.6 alkyl or R.sup.3 and R.sup.4 together may be a ##STR2## group wherein n is an integer of from 0 to 4; and X, Y and Z are independently--CH-- or --N.dbd. provided that one and only one of X, Y or Z must be --N.dbd..The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions as anti-anaerobic agents.

Abstract: The present invention relates to a class of novel substituted alkyl imidazole compounds that are useful as intermediates and as anti-anaerobic agents.

Abstract: The present invention relates to a class of novel substituted alkyl imidazole compounds that are useful as anti-anaerobic agents. The present invention further relates to pharmaceutical compositions that contain such compounds and are also useful as anti-anaerobic agents. The compounds are of the formula ##STR1## wherein A, R.sup.1, R.sup.2 and n are defined hereinbelow.

Abstract: Imidazoline derivatives of the formula ##STR1## wherein R.sup.1 is hydrogen or alkyl C.sub.1-6 ;R.sup.2 is hydrogen, methyl, chloro, bromo or fluoro;R.sup.3 is hydrogen, methyl, hydroxy, methoxy, fluoro, chloro or bromo; and their non-toxic salts.Processes for their preparation and pharmaceutical compositions thereof. The compounds exhibit presynaptic .alpha..sub.2 -adrenoreceptor antagonist activity.

Abstract: Imidazoline derivatives of the formula ##STR1## wherein R.sup.1 is alkyl C.sub.1-7, alkenyl C.sub.2-4, cycloalkenyl C.sub.4-7, cycloalkyl C.sub.4-7 or phenyl; and their non-toxic salts.Processes for the preparation and pharmaceutical compositions thereof. The compounds exhibit presynaptic .alpha..sub.2 -adrenoreceptor antagonism.